Hudson Bay Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.9M Buy
950,000
+700,000
+280% +$33.2M 0.12% 142
2025
Q4
$12.7M Buy
+250,000
New +$12.8M 0.04% 296
2025
Q1
Sell
-107,200
Closed -$9.22M 1424
2024
Q4
$9.22M Buy
+107,200
New +$11.6M 0.03% 383

Other funds holding NVO

Hudson Bay Capital Management's NVO Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Novo Nordisk (NVO) stake by 76% in Q1 2026, selling an estimated $19.2M and leaving 125,038 shares worth $4.6M. The position accounts for 0.02% of the portfolio, ranked #536.

Hudson Bay Capital Management first reported a position in NVO in Q3 2022 and has held it in 9 quarters since. The position peaked at $55.2M in Q4 2024. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Hudson Bay Capital Management held 125,038 shares of Novo Nordisk worth $4.6M as of Q1 2026.
  • Hudson Bay Capital Management sold 404,165 Novo Nordisk shares in Q1 2026, an estimated $19.2M.
  • Novo Nordisk made up 0.02% of Hudson Bay Capital Management's portfolio in Q1 2026, its #536 holding.
  • Hudson Bay Capital Management first reported a position in Novo Nordisk in Q3 2022 and has held it in 9 quarters since.
  • Hudson Bay Capital Management's Novo Nordisk position peaked at $55.2M in Q4 2024.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.